Xeris Biopharma Cash Flow Statement
NASDAQ: XERSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
10.48+0.29 (+2.85%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Xeris Biopharma free cash flow
In fiscal 2025, Xeris Biopharma generated $28.6 million of operating cash flow. That left free cash flow of $28.6 million, a free-cash-flow margin of 9.8% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
Xeris Biopharma cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 |
|---|---|---|---|---|---|---|
| Net Income | 554.00K | -54.84M | -62.26M | -94.66M | -122.72M | -91.14M |
| Net Income growth (YoY) | — | — | — | — | — | — |
| Depreciation & Amortization | 1.31M | 1.23M | 1.49M | 1.40M | 1.33M | 1.47M |
| Stock-Based Compensation | 22.37M | 18.36M | 10.72M | 12.16M | 11.38M | 8.27M |
| Change in Working Capital | -26.27M | -20.68M | -12.82M | -22.65M | -9.31M | -6.61M |
| Operating Cash Flow | 28.63M | -36.98M | -47.02M | -102.89M | -95.53M | -80.56M |
| Capital Expenditures | — | — | — | — | -1.08M | -377.00K |
| Investing Cash Flow | -696.00K | 4.88M | -6.00M | 34.46M | 97.96M | -27.41M |
| Debt Issued | — | 0 | 0 | 146.21M | 0 | 94.84M |
| Debt Repaid | — | 0 | 0 | -43.50M | 0 | -25.09M |
| Financing Cash Flow | 11.39M | 36.17M | -1.61M | 127.47M | 27.25M | 126.06M |
| Net Change in Cash | 39.32M | 4.07M | -54.64M | 59.04M | 29.67M | 18.08M |
| Free Cash Flow | 28.63M | -36.98M | -47.02M | -102.89M | -96.62M | -80.94M |
This table shows 6 annual periods of Xeris Biopharma's cash flow statement, from FY 2025 back to FY 2020, across 12 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow XERS's reporting calendar. What is a cash flow statement?